ArchivesMagazine - 13 Nov 2014Momentum builds at Abcam Life sciences play benefits from new products and market growth 13 November 2014|Feature|by Mark Dunne Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < Super Investors TT looks unexceptional > Issue: 13 Nov 2014 - Page 54 | Contents Next: TT looks unexceptional Previous: Super Investors Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Mark Dunne Issue Contents Chartist Ride the US rollercoaster Feature Deciphering profit warnings Preview: Entertainment One Super Investors Returning the shine to Stellar Best & Worst Performing Small Caps Table Omega has recovery potential Finsbury’s tasty transaction The most loved and unloved stocks LSE to launch mid-day auction Structured products explained Bulls line up for Euro Weighing up stimulus moves China’s lottery phenomenon Feast on a high-fibre diet Director dealings: Top buys and sells Momentum builds at Abcam Time to back Tate The Best & Worst Performers: FTSE 350, Global Market, Commodities, Forex, Sovereign Yields The Best & Worst Performers: FTSE 350, Global Market, Commodities, Forex, Sovereign Yields Fight For Your Rights Taxing questions for PLCs Fixed-Income Focus Correction Funds Harvest Asian returns News Dairy Crest’s milk money Banks in the firing line Licence to drill Fidessa optimism unfounded News in brief: Flowgroup, Serco, Trifast, Findel, Mortgage Advice Bureau, Central Rand Gold, Avanta Serviced Office, Fusionex, Plexus Chart of the week: Winter wonderland Cambian’s profit drive E2V’s revamp challenges Plays Repeating the trick Switch on to UTV Media Plays update: Experian Plays update: Marks & Spencer Plays update: Bank of Georgia Plays update: Gulf Marine Services Trading Strategies Turbo charge your returns Under The Bonnet TT looks unexceptional
